hrp0095p1-329 | Growth and Syndromes | ESPE2022

Associations between Eating Patterns of Adolescents and Their Height and Weight, A Comparison Between Genders

Zur Maya , Fisch-Shvalb Naama , Phillip Moshe , Yackobovitch-Gavan Michal

Rationale: Adequate nutrition is essential for normal growth in childhood and adolescence. The high growth rate during adolescence demands high amounts of energy and various nutrients. During puberty, unlike infancy and early childhood, boys and girls of the same age have gender-specific nutritional needs. Our aim was to examine the associations between the dietary intake of male and female adolescents and their anthropometric measures.<...

hrp0095p2-138 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Hypoglycemia in children: Clinical experience of a tertiary care center

Gil Margolis Merav , Lilos Pearl , Phillip Moshe , de Vries Liat

Introduction: Hypoglycemia is a significant cause of morbidity in children, yet is challenging to diagnose and treat due to its heterogeneity.Aim: To describe the diagnoses and clinical characteristics of children with hypoglycemia referred to a tertiary pediatric center.Methods: This retrospective study included 155 children (86 males, aged 0-18 years) diagnosed with hypoglycemia ...

hrp0089p3-p277 | Multisystem Endocrine Disorders P3 | ESPE2018

Wolman Disease: Long-Term Endocrine and Metabolic Comorbidities

Bello Rachel , Stein Jerry , Phillip Moshe , Shalitin Shlomit

Introduction: Wolman Disease [WD] is a rare, autosomal recessive disease caused by lysosomal acid lipase deficiency and characterized by accumulation of cholesterol-esters and triglycerides primarily in the liver and spleen. Patients present within the first year of life with a rapidly progressive disease.Case: A girl born to consanguineous parents was diagnosed with WD due to characteristic manifestations and family history (genetically confirmed). At t...

hrp0086p1-p635 | Growth P1 | ESPE2016

Glucagon vs Clonidine Stimulation for Testing Growth Hormone Secretion in Children and Adolescents: Which is Better?

Asher Galit , Diament Rotem , Phillip Moshe , Lebenthal Yael

Background: The definitive diagnosis of childhood GH deficiency (GHD) depends on the demonstration of failure to respond to two stimuli. In our center children are allocated to either glucagon-first or clonidine-first according to the preference of the pediatric endocrinologist following the patient. The nursing staff prefer glucagon-first due to patient safety (less pronounced adverse events and faster recovery time). Few studies have addressed which GH stimulation test shoul...

hrp0082p2-d1-266 | Adrenals &amp; HP Axis | ESPE2014

Is Basal 17-Hydroxyprogesterone a Sensitive Marker for Diagnosis of Non-Classical Congenital Adrenal Hyperplasia?

Bello Rachel , Lebenthal Yael , Phillip Moshe , de Vries Liat

Background: A basal 17-hydroxyprogesterone (17-OHP) plasma level of 6.0 nmol/l was suggested as a threshold for the diagnosis of non-classical congenital adrenal hyperplasia (NCCAH), particularly in children presenting with precocious pubarche (PP).Objective: The present study aimed to determine if this threshold could lead to underdiagnosis of NCCAH.Method: In a retrospective study the cohort of pediatric patients (n=145,...

hrp0094wg3.3 | ESPE Working Group on Diabetes Technology (DT) Symposium | ESPE2021

The impact of fear of hyperglycemia in parents of children with type 1 diabetes mellitus on overall glycemic control

Liberman Alon , Nevo-Schenker Michal , Sachar-Lavie Iris , Phillip Moshe ,

Background: Achieving proper glycemic control is the major goal in the management of type 1 diabetes. The Diabetes Control and Complication Trial showed that optimal glycemic control can decrease micro- and macrovascular complications in adolescents and adults with type 1 diabetes. Both hypo and hyperglycemia affect crucial regions in the developing brain. In children and young adolescents, most of the work towards achieving optimal glycemic control is led by ...

hrp0097p1-206 | Adrenals and HPA Axis | ESPE2023

Adrenal insufficiency is not a common cause of hypoglycemia in children

Gil Margolis Merav , Lilos Pearl , Phillip Moshe , de Vries Liat

Background: Hypoglycemia etiology in children is heterogeneous and varies by age. Both growth hormone (GH) and cortisol deficiencies may present with hypoglycemia; the latter may result in an adrenal crisis that may be fatal.Objectives: To evaluate responses of cortisol and GH to spontaneous hypoglycemia in infants and children, and to assess the rate of true cortisol deficiency in children, defined as cortisol<500 nm...

hrp0084p2-309 | DSD | ESPE2015

Alterations in Germ Cell Memory and Mini-Puberty Induce Infertility in Cryptorchidism

Hadziselimovic Faruk , Docampo-Garcia Maria-Jose , Hadziselimovic Nils , Kray Gunthild , Demougin Philipp

Background: Spermatogonia contain processing bodies (P-bodies) that harbour P-element induced wimpy testis (Piwi) proteins associated specifically with Piwi-interacting RNAs to silence transposable DNA elements. In mice loss-of-function mutations in the Piwi pathway lead to de-repression of transposable elements, resulting in male-specific sterility.Objective and hypotheses: No previous studies have examined expression of transposons silencing gene micro...

hrp0095fc7.2 | Growth and Syndromes | ESPE2022

Post-hoc subgroup analysis of the pivotal phase 3 study of once-weekly somatrogon vs once-daily Genotropin: results from subjects with peak stimulated growth hormone value <6.7 ng/ml

Phillip Moshe , Deal Cheri , Silverman Lawrence , Henocque Robin , Nijher Monica , Wajnrajch Michael , Wang Ronnie , Cara Jose

Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) approved by the EMA as a once weekly treatment for children with GH deficiency (GHD). The peak stimulated GH cut-off value for diagnostic criteria for GHD varies according to country-specific guidelines. The objective of this subgroup analysis of the pivotal phase 3 somatrogon study was to evaluate the primary and secondary efficacy endpoints for subjects with a peak GH value <6.7...

hrp0095p1-134 | Growth and Syndromes | ESPE2022

Applying personalized medicine- From a unique endo-genetic clinic to a national project of certifying endocrinologists to perform genetic consults and testing

Shefer Averbuch Noa , Orenstein Naama , Greenberg Rotem , Ben-Shachar Shay , Phillip Moshe

Background: The rapid advancement in understanding molecular mechanisms, and the availability of genetic testing, has led to a paradigm change in many endocrine disorders. Making an accurate diagnosis enables tailored follow-up, treatment, and family genetic counselling. However, a cooperation is required, since the endocrinologist has a more profound understanding of the disorders, but the geneticist is usually better skilled in analyzing genetic results and ...